MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
The Pharma Data
JANUARY 10, 2021
MorphoSys Forward-Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi’s ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including (..)
Let's personalize your content